Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-80 years of age;~* RA for \>=3 months;~* receiving outpatient treatment;~* failed treatment with \>=1 DMARD (but not anti TNF or other biologic therapy);~* inadequate response to methotrexate, having taken and tolerated it for \>=12 weeks, with a stable dose for \>=4 weeks.~Exclusion Criteria:~* rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;~* history of, or current, inflammatory joint disease other than RA, or other systemic autoimmune disorder;~* diagnosis of RA before the age of 16;~* bone/joint surgery within 12 weeks of study;~* prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).